{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:30:44Z","timestamp":1793226644631,"version":"4.5.0"},"reference-count":50,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["A&amp;amp;D Transl Res &amp;amp; Clin Interv"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION<\/jats:title>\n                    <jats:p>The glucagon\u2010like peptide\u20101 receptor agonist semaglutide may impact neuroinflammation and reduce neurodegeneration. We present baseline characteristics of participants enrolled in the evoke (NCT04777396) and evoke+ (NCT04777409) trials, referred to as \u201cevoke (+)\u201d hereafter.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Evoke (+) are two ongoing global, multicenter, randomized, double\u2010blind, parallel\u2010group, placebo\u2010controlled phase 3 trials investigating semaglutide in participants with early\u2010stage symptomatic Alzheimer's disease (AD) with confirmed amyloid positivity (by positron emission tomography or cerebrospinal fluid testing). Inclusion criteria are the same for both trials, except that by design, evoke+ also includes participants with significant small vessel pathology. Both trials include a 12\u2010week screening phase before randomization (1:1) to receive oral semaglutide titrated to 14\u00a0mg or placebo for 156 weeks. Baseline data were summarized and analyzed descriptively. Additionally, data were pooled and assessed by five main geographical regions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Evoke (+) recruited 9996 participants from 566 sites in 40 countries. The mean (standard deviation) age of participants was 71.8 (7.1) and 72.6 (7.1) years in evoke and evoke+, respectively; more participants were female than male (female: 53.0% and 51.9%, respectively) and most had a Clinical Dementia Rating (CDR) global score of 0.5 (72.8% and 71.4%; CDR global score of 1: 26.5% and 27.6%). Both trial populations had similar demographics, and clinical and cognitive baseline characteristics, except that 2.8% of participants in evoke+ had magnetic resonance imaging\u2010documented significant small vessel pathology as per protocol inclusion criteria. Regional\u2010level data demonstrated some differences in AD treatment characteristics, including cholinesterase inhibitor use of 41.7% in North America versus 61.6% in Asia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION<\/jats:title>\n                    <jats:p>Evoke (+) are the only large\u2010scale, phase 3 trials investigating the longer\u2010term efficacy and safety of semaglutide in early AD as a potential disease\u2010modifying treatment. The baseline characteristics from evoke (+) reflect a varied, global population with early\u2010stage symptomatic AD. Primary readouts are expected in the second half of 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Highlights<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>evoke and evoke+ are the only large\u2010scale randomized controlled trials (RCTs) investigating the longer\u2010term efficacy and safety of semaglutide in early AD.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Baseline characteristics reflect a varied, global population.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The trials\u2019 primary readouts\u00a0are expected in the second half of 2025.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/trc2.70200","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T08:25:28Z","timestamp":1768033528000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo\u2010controlled trials of semaglutide in participants with early\u2010stage symptomatic Alzheimer's disease"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1046-6408","authenticated-orcid":false,"given":"Philip","family":"Scheltens","sequence":"first","affiliation":[{"name":"Alzheimer Center Department of Neurology Vrije Universiteit Amsterdam Amsterdam UMC  Amsterdam Netherlands"},{"name":"EQT Life Sciences  Amsterdam Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Atri","sequence":"additional","affiliation":[{"name":"Banner Sun Health Research Institute  Sun City Arizona USA"},{"name":"Banner Alzheimer's Institute  Phoenix Arizona USA"},{"name":"Brigham and Women's Hospital Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard H.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Alzheimer's Disease Cooperative Study Department of Neurosciences University of California San Diego  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry Institute of Neuroscience and Physiology Sahlgrenska Academy University of Gothenburg  M\u00f6lndal Sweden"},{"name":"Clinical Neurochemistry Laboratory Sahlgrenska University Hospital  M\u00f6lndal Sweden"},{"name":"Department of Neurodegenerative Disease UCL Queen Square Institute of Neurology  London UK"},{"name":"UK Dementia Research Institute at UCL  London UK"},{"name":"Hong Kong Center for Neurodegenerative Diseases InnoHK  Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Sano","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai  New York New York USA"},{"name":"James J Peters VAMC  Bronx New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Johannsen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa Le\u00f3n","family":"Colombo","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bardtrum","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Jeppesen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte T.","family":"Hansen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Cummings","sequence":"additional","affiliation":[{"name":"Chambers\u2010Grundy Center for Transformative Neuroscience Department of Brain Health Kirk Kerkorian School of Medicine University of Nevada Las Vegas  Las Vegas Nevada USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1159\/000543578"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13859"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.109"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12694"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(20)30925\u20109"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u2010190426"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41514\u2010024\u201000136\u20106"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12385"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259\u2010023\u201000633\u20102"},{"key":"e_1_2_9_11_1","unstructured":"U.S. Food and Drug Administration.RYBELSUS Prescribing Information. Accessed June 18 2025.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/213051s000lbl.pdf"},{"key":"e_1_2_9_12_1","unstructured":"U.S. Food and Drug Administration.OZEMPIC Prescribing Information. Accessed June 18 2025.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209637lbl.pdf"},{"key":"e_1_2_9_13_1","unstructured":"U.S. Food and Drug Administration.WEGOVY Prescribing Information. Accessed June 18 2025.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215256s000lbl.pdf"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s42003\u2010021\u201002208\u20109"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40478\u2010021\u201001180\u2010z"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010020\u201018249\u20103"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010018\u20100109\u20104"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010018\u20100051\u20105"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2018.09.004"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.14336\/ad.2021.1029"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/strokeaha.121.037775"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101737"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23772"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells11162587"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2016.00108"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm919"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.01112"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.10611"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE\u201019\u20100259"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/1533317519899546"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102689"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102726"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12268"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010024\u201001666\u20107"},{"key":"e_1_2_9_35_1","unstructured":"ClinicalTrials.gov.A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE). Accessed June 18 2025.https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04777396"},{"key":"e_1_2_9_36_1","unstructured":"ClinicalTrials.gov.A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus). Accessed June 18 2025.https:\/\/clinicaltrials.gov\/study\/NCT04777409?term=NCT04777409amp;rank=1"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0029665112002753"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151710"},{"key":"e_1_2_9_39_1","unstructured":"European Medicines Agency.2024.Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8\u201311 April 2024. Accessed June 18 2025.https:\/\/www.ema.europa.eu\/en\/news\/meeting\u2010highlights\u2010pharmacovigilance\u2010risk\u2010assessment\u2010committee\u2010prac\u20108\u201011\u2010april\u20102024"},{"key":"e_1_2_9_40_1","unstructured":"U.S. Food and Drug Administration.2024.Update on FDA's ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity. Accessed June 18 2025.https:\/\/www.fda.gov\/drugs\/drug\u2010safety\u2010and\u2010availability\/update\u2010fdas\u2010ongoing\u2010evaluation\u2010reports\u2010suicidal\u2010thoughts\u2010or\u2010actions\u2010patients\u2010taking\u2010certain\u2010type"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12737"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010023\u201001177\u2010x"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12389"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.50"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40615\u2010016\u20100283\u20103"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt188"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.3233\/jad\u2010201081"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304430"}],"container-title":["Alzheimer's &amp; Dementia: Translational Research &amp; Clinical Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/trc2.70200","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/trc2.70200","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/trc2.70200","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T23:53:28Z","timestamp":1775865208000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/trc2.70200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/trc2.70200"],"URL":"https:\/\/doi.org\/10.1002\/trc2.70200","archive":["Portico"],"relation":{},"ISSN":["2352-8737","2352-8737"],"issn-type":[{"value":"2352-8737","type":"print"},{"value":"2352-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-09-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70200"}}